IDT Australia is poised for its strongest FY26 finish since its transformation began, forecasting a dramatic narrowing of EBITDA losses and revenue growth driven by strategic partnerships and operational upgrades.
- FY26 EBITDA loss forecast narrows 68%-76%
- Revenue from three verticals expected to grow 4%-11%
- Sanofi names IDT a Preferred Vendor
- US policy shifts boost psychedelics and medicinal marijuana demand
- Recommissioned facilities improve manufacturing efficiency
Sharp Earnings Improvement Despite Q3 Setbacks
IDT Australia Limited (ASX:IDT) is on track to deliver its strongest fourth quarter performance since initiating its transformation program over two years ago, despite a challenging March quarter. The company’s Q3-FY26 revenue fell 25.2% year-on-year to $2.6 million due to scheduled maintenance shutdowns and commissioning of key facilities, which also caused a 37.7% quarter-on-quarter decline. However, the full-year outlook is far more optimistic, with IDT forecasting EBITDA losses to shrink dramatically to between $1.5 million and $2 million, a 68%-76% improvement on FY25’s $6.3 million loss. Operating revenue from its three core verticals is expected to rise by 4%-11% to between $15 million and $16 million for FY26.
This marks a continuation of the company’s strategic realignment under new management, focused on cost optimisation and securing higher-value, repeatable contracts. The business is set to benefit from a $2 million cost savings initiative slated for FY27, reinforcing its resilience amid ongoing economic disruptions and rising fuel costs. The momentum builds on earlier progress, including a 20.3% revenue increase and substantial EBITDA loss reduction reported in February, which highlighted the early success of IDT’s reset efforts 20.3% revenue increase and EBITDA loss reduction.
Sanofi Partnership Elevates IDT’s Global Profile
IDT’s designation as a Preferred Vendor by global pharmaceutical giant Sanofi is a standout development. This coveted status follows successful support in developing Sanofi’s new mRNA vaccines and opens the door for IDT to pitch for additional projects across multiple business units and therapeutic areas. The endorsement from Sanofi not only validates IDT’s manufacturing quality and reliability but also enhances its credibility in the competitive contract development and manufacturing organisation (CDMO) sector.
Further amplifying its global reach, IDT has formed a strategic partnership with Fierce Pharma, a leading industry media and events organisation. This alliance will see IDT participate in Fierce Biotech Week in Boston, presenting its capabilities to senior pharma decision-makers. Sanofi’s public support at the upcoming event adds an influential voice endorsing IDT’s execution capabilities, potentially accelerating contract wins in sterile fill and API manufacturing markets.
US Regulatory Shifts Open New Growth Avenues
The evolving US policy landscape around psychedelics and medicinal marijuana is another tailwind for IDT. Recent federal moves, including directives from President Donald Trump to ease barriers and provide financial support for psychedelic drug development, are reshaping the market environment. IDT anticipates increased demand for its API and Specialty Orals verticals, capitalising on opportunities in psychedelic-assisted therapies and cannabinoid-based medicines. This aligns with the company’s strategic focus on controlled-drug sectors, where it has already secured new contracts from emerging US manufacturers and distributors.
Operational Upgrades Boost Profitability and Capacity
IDT’s multi-year program to recommission mothballed manufacturing assets is beginning to pay dividends. Key facilities, including a 4,000-litre API plant and a sterile fill-finish line, have been brought back online, enhancing operational flexibility and reducing marginal costs by spreading fixed overheads over greater production volumes. This upgrade improves IDT’s competitiveness for global CDMO contracts, particularly where rapid turnaround and quality are critical. Increased utilisation of these assets is already evident, supporting expectations for a strong Q4-FY26 rebound.
The company’s strategic approach continues to prioritise API manufacturing as a cornerstone, with a focus on clients possessing robust pipelines to generate flow-on contracts across Specialty Orals and Sterile Fill verticals. While Q3 revenue dips reflect contract progression shifts, management expects a rebound in API work in the current quarter. Specialty Orals is sharpening its focus on radiopharmaceuticals alongside medicinal cannabis and psychedelics, while Sterile Fill aims to capture high-value programs involving emerging mRNA technologies.
These operational and strategic shifts build on the groundwork laid in previous quarters, including securing $3.4 million in contracts and targeting significant cost savings, which have been instrumental in reshaping IDT’s trajectory $3.4 million contracts and cost savings.
Executive Chair Signals Confidence in Near-Term Profitability
Mark Simari, IDT’s Executive Chair, emphasised the progress made in optimising resource allocation and focusing on recurring revenue from quality customers. He highlighted that these changes signify an important evolution in IDT’s business model, positioning the company to return to profitability in the near term and drive growth beyond FY26. The company’s strategic reset is clearly moving beyond early-stage adjustments towards tangible financial improvements and market repositioning.
Bottom Line?
IDT’s FY26 guidance signals a turning point with a sharply reduced EBITDA loss and growth prospects tied to strategic partnerships and regulatory tailwinds, but execution in Q4 and sustained contract wins will be critical to validate this momentum.
Questions in the middle?
- Will IDT sustain revenue growth beyond FY26 amid evolving US psychedelics policy?
- How effectively will IDT convert its Preferred Vendor status with Sanofi into new contracts?
- Can recommissioned facilities maintain higher utilisation and margin improvements long term?